RVNCのチャート
RVNCの企業情報
| symbol | RVNC |
|---|---|
| 会社名 | Revance Therapeutics Inc （レバンス・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 レバンス・セラピューティクス(Revance Therapeutics Inc.)は臨床段階のバイオテクノロジー会社である。同社は美容及び治療的適応症のためのボツリヌス毒素製品の開発、製造及び商業化に従事する。同社のペプチド技術は、注射用ダキシボトリュームトキシンA（RT002）または注射可能RT002及びダキシボチュリントキシンA局所用ゲル（RT001）またはRT001注射剤という2つの治験薬品候補を通じてA型ボツリヌス毒素を送達する。同社はRT002注射剤の臨床開発に従事する。RT002注射剤は生理食塩水ベースの製剤中でボツリヌス毒素 - ペプチド複合体を利用する。RT002注射剤はペプチドは標的筋肉の細胞外構造及び細胞表面受容体と相互作用する。この相互作用は毒素分子を標的部位に制限し、隣接筋肉への広がりを減少させる。同社はグラベラ・ライン、頸部ジストニア及び足底筋膜炎の治療のためのRT002の開発を行う。 レバンス・セラピュ―ティクスは米国のバイオ医薬品メ―カ―。審美及び治療応用のためのボツリヌス毒素製品の開発、製造、商業化に従事。主要製品候補の「RT001」は、独自の技術による注射の必要のないゲルタイプのボツリヌス毒素製品。また、注射タイプの「RT002」は、ボツリヌス毒素の深い浸透により、より長い持続効果が期待される。 Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval. Revance is also evaluating DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines and crow's feet, as well as in two therapeutic indications - cervical dystonia and adult upper limb spasticity. To accompany DaxibotulinumtoxinA for Injection, Revance owns a unique portfolio of premium products and services for U.S. aesthetics practices, including the exclusive U.S. distribution rights to the RHA® Collection of dermal fillers, the first and only range of FDA-approved fillers for correction of dynamic facial wrinkles and folds, and the HintMD fintech platform, which provides an integrated smart payment solution that supports aesthetic practice management, practice economics and practice loyalty. Revance has also partnered with Viatris (formerly Mylan N.V.) to develop a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace. Revance is dedicated to making a difference by transforming patient experiences. |
| 本社所在地 | 7555 Gateway Boulevard Newark CA 94560 USA |
| 代表者氏名 | Angus Charles Russell アンガス・チャールズ・ラッセル |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 510-742-3400 |
| 設立年月日 | 36373 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2014年 |
| 従業員数 | 134人 |
| url | www.revance.com |
| nasdaq_url | https://www.nasdaq.com/symbol/rvnc |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -132.59800 |
| 終値（lastsale） | 23.57 |
| 時価総額（marketcap） | 870626090.87 |
| 時価総額 | 時価総額（百万ドル） 884.66250 |
| 売上高 | 売上高（百万ドル） 0.99100 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 650.92850 |
| 当期純利益 | 当期純利益（百万ドル） -135.67500 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Revance Therapeutics Inc revenues increased from $150K to $879K. Net loss increased 28% to $69.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Selling and Adminstative balance increase of 75% to $21.8M (expense) Research_Development balance increase of 18% to $41.3M (expense). |
RVNCのテクニカル分析
RVNCのニュース
Do investors need to be concerned about Revance Therapeutics Inc. (RVNC)? 2022/12/02 15:24:00 US Post News
Revance Therapeutics Inc. (NASDAQ:RVNC) marked $21.76 per share on Thursday, up from a previous closing price of $21.71. While Revance Therapeutics Inc. has overperformed by 0.23%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RVNC rose by 53.35%, with highs and lows ranging from $30.95 to […]
Revance Therapeutics Inc. (NASDAQ:RVNC) Could Actually Go To $65.00 In 12 Months 2022/11/26 15:00:00 Marketing Sentinel
In last trading session, Revance Therapeutics Inc. (NASDAQ:RVNC) saw 0.29 million shares changing hands with its beta currently measuring 0.54. Company’s recent per share price level of $23.01 trading at $0.22 or 0.97% at ring of the bell on the day assigns it a market valuation of $1.84B. That closing price of RVNC’s stock is … Revance Therapeutics Inc. (NASDAQ:RVNC) Could Actually Go To $65.00 In 12 Months Read More »
A stock that deserves closer examination: Revance Therapeutics Inc. (RVNC) 2022/11/23 14:32:00 US Post News
The share price of Revance Therapeutics Inc. (NASDAQ:RVNC) rose to $22.68 per share on Tuesday from $22.10. While Revance Therapeutics Inc. has overperformed by 2.62%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RVNC rose by 62.46%, with highs and lows ranging from $30.95 to $11.27, […]
Can you now get a good deal on Revance Therapeutics Inc.’s shares? 2022/11/17 14:08:00 US Post News
As of Wednesday, Revance Therapeutics Inc.’s (NASDAQ:RVNC) stock closed at $23.15, down from $23.76 the previous day. While Revance Therapeutics Inc. has underperformed by -2.57%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RVNC rose by 58.13%, with highs and lows ranging from $30.95 to $11.27, […]
Revance Therapeutics: FDA Approval Of Daxxify Only One Part Of The Journey (NASDAQ:RVNC) 2022/11/14 21:27:07 Seeking Alpha
FDA approval of DAXXIFY for the treatment of patients with glabellar (frown) lines already obtained by Revance Therapeutics, Inc.
Do investors need to be concerned about Revance Therapeutics Inc. (RVNC)? 2022/12/02 15:24:00 US Post News
Revance Therapeutics Inc. (NASDAQ:RVNC) marked $21.76 per share on Thursday, up from a previous closing price of $21.71. While Revance Therapeutics Inc. has overperformed by 0.23%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RVNC rose by 53.35%, with highs and lows ranging from $30.95 to […]
Revance Therapeutics Inc. (NASDAQ:RVNC) Could Actually Go To $65.00 In 12 Months 2022/11/26 15:00:00 Marketing Sentinel
In last trading session, Revance Therapeutics Inc. (NASDAQ:RVNC) saw 0.29 million shares changing hands with its beta currently measuring 0.54. Company’s recent per share price level of $23.01 trading at $0.22 or 0.97% at ring of the bell on the day assigns it a market valuation of $1.84B. That closing price of RVNC’s stock is … Revance Therapeutics Inc. (NASDAQ:RVNC) Could Actually Go To $65.00 In 12 Months Read More »
A stock that deserves closer examination: Revance Therapeutics Inc. (RVNC) 2022/11/23 14:32:00 US Post News
The share price of Revance Therapeutics Inc. (NASDAQ:RVNC) rose to $22.68 per share on Tuesday from $22.10. While Revance Therapeutics Inc. has overperformed by 2.62%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RVNC rose by 62.46%, with highs and lows ranging from $30.95 to $11.27, […]
Can you now get a good deal on Revance Therapeutics Inc.’s shares? 2022/11/17 14:08:00 US Post News
As of Wednesday, Revance Therapeutics Inc.’s (NASDAQ:RVNC) stock closed at $23.15, down from $23.76 the previous day. While Revance Therapeutics Inc. has underperformed by -2.57%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RVNC rose by 58.13%, with highs and lows ranging from $30.95 to $11.27, […]
Revance Therapeutics: FDA Approval Of Daxxify Only One Part Of The Journey (NASDAQ:RVNC) 2022/11/14 21:27:07 Seeking Alpha
FDA approval of DAXXIFY for the treatment of patients with glabellar (frown) lines already obtained by Revance Therapeutics, Inc.
Revance Therapeutics (RVNC) Shares Cross Above 200 DMA 2022/07/19 15:58:47 Nasdaq
In trading on Tuesday, shares of Revance Therapeutics Inc (Symbol: RVNC) crossed above their 200 day moving average of $15.76, changing hands as high as $15.81 per share. Revance Therapeutics Inc shares are currently trading up about 6.5% on the day. The chart below shows the
Revance Therapeutics Inc. (RVNC): A New Perspective 2022/07/02 17:00:00 Stocks Register
Revance Therapeutics Inc. (NASDAQ:RVNC) concluded the trading at $14.33 on Friday, July 01 with a rise of 3.69% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $13.82 and 5Y monthly beta was reading 1.00 with its price kept floating in the … Revance Therapeutics Inc. (RVNC): A New Perspective Read More »
Is Revance Therapeutics (RVNC) a Worthy Investment Pick? 2022/06/15 12:19:35 Insider Monkey
Baron Funds, an asset management firm, published its “Baron Discovery Fund” first quarter 2022 investor letter – a copy of which can be downloaded here.
Metrics That Matter About Revance Therapeutics Inc. (NASDAQ: RVNC) 2022/06/04 17:00:00 Stocks Register
Revance Therapeutics Inc. (NASDAQ:RVNC) shares, rose in value on Friday, 06/03/22, with the stock price up by 0.08% to the previous day’s close as strong demand from buyers drove the stock to $13.30. Actively observing the price movement in the last trading, the stock closed the session at $13.29, falling within a range of $13.03 … Metrics That Matter About Revance Therapeutics Inc. (NASDAQ: RVNC) Read More »
Revance Therapeutics''s (RVNC) CEO Mark Foley On Q1 2022 Results - Earnings Call Transcript 2022/05/11 03:00:04 Seeking Alpha
Revance Therapeutics, Inc. (NASDAQ:NASDAQ:RVNC) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Jessica Serra – Head-Investor Relations and ESG Mark Foley –…